A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- ENDOCRINE JOURNAL62(5) · pp.449 · 2015
- 피인용
- Web of Science 15
- JCR IF
- JCR 2014 1.997
- ISSN
- 0918-8959
저자
- Yang, Hae Kyung제1저자Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
- Min, Kyung WanDiabetes Center, Eulji General Hospital, Eulji University School of Medicine, Seoul, South Korea
- Park, Sung WooDiabetes Research Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Chung, Choon HeeDepartment of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, South Korea
- Park, Kyong SooDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea
- Choi, Sung HeeDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
- Song, Ki-HoDivision of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St.Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
- Kim, Doo-ManDepartment of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, South Korea
- Lee, Moon-KyuDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Sung, Yeon-AhDepartment of Internal Medicine, Ewha Womans University School of Medicine, South, South Korea
- Baik, Sei HyunDivision of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea
- 김인주Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea
- Cha, Bong-SooDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
- Park, Jeong HyunDepartment of Internal Medicine, Busan Paik Hospital, College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea
- Ahn, Yu BaeDivision of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea
- Lee, In-KyuDivision of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Aging and Metabolism, Kyungpook National University School of Medicine, Daegu, South Korea
- Yoo, Soon JibDivision of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, South Korea
- Kim, JaetaekDivision of Endocrinology and Metabolism, Department of Internal Medicine, Chung-Ang University, Seoul, South Korea
- Park, Ie ByungDivision of Endocrinology and Metabolism, Gachon University, Gil Medical Center, Incheon, South Korea
- Park, Tae SunDivision of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, South Korea
- Yoon, Kun-Ho교신저자Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
초록
The aim of this study was to evaluate the efficacy and safety of anagliptin in drug-nave patients with type 2 diabetes in a double-blind randomized placebo-controlled study. A total of 109 patients were randomized to 100 mg (n=37) or 200 mg (n=33) anagliptin twice daily or placebo (n=39). The primary objective was to alter HbA1c levels from baseline at a 24-week endpoint. The overall baseline mean age and body mass index were 56.20 +/- 9.77 years and 25.01 +/- 2.97 kg/m(2), respectively, and the HbA1c level was of 7.14 +/- 0.69 %. Anagliptin at 100 mg and 200 mg produced significant reductions in HbA1c (-0.50 +/- 0.45 % and -0.51 +/- 0.55%, respectively), and the placebo treatment resulted in an increase in HbA1c by 0.23 +/- 0.62 %. Both doses of anagliptin produced significant decreases in fasting plasma glucose (-0.53 +/- 1.25 mmol/L and -0.72 +/- 1.25 mmol/L, respectively) and the proinsulin/insulin ratio (-0.04 +/- 0.15 and -0.07 +/- 0.18, respectively) compared with placebo. No meaningful body weight changes from baseline were observed in three groups. Plasma dipeptidyl peptidase (DPP)-4 activity was significantly inhibited after 24 weeks of anagliptin treatment, and >75% and >90% inhibitions were observed during the meal tolerance tests with 100 mg and 200 mg anagliptin, respectively. The incidences of adverse or serious adverse events were similar among the three study groups. Twice-daily anagliptin therapy effectively inhibited DPP-4 activity and improved glycemic control and was well-tolerated in patients with type 2 diabetes.
키워드
DPP-4 inhibitorGlycemic controlType 2 diabetesDIPEPTIDYL PEPTIDASE-4 INHIBITORGLUCOSE-LOWERING EFFICACYGLYCEMIC CONTROLDPP-4 INHIBITORVILDAGLIPTINMONOTHERAPYSITAGLIPTINTOLERABILITYMICE
식별자
- WoS UID
- 000357440600008



로그인
연구물 목록으로